Rindi G, Wiedenmann B (2020) Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine. Nat Rev Endocrinol 16(10):590–607

Article  PubMed  Google Scholar 

Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072

Article  PubMed  Google Scholar 

Sahani DV, Bonaffini PA, Fernández-Del Castillo C et al (2013) Gastroenteropancreatic neuroendocrine tumors: role of imaging in diagnosis and management. Radiology 266(1):38–61

Article  PubMed  Google Scholar 

Nagtegaal ID, Odze RD, Klimstra D et al (2020) The 2019 WHO classification of tumours of the digestive system. Histopathology 76(2):182–188

Article  PubMed  Google Scholar 

Assarzadegan N, Montgomery E (2021) What is New in the 2019 World Health Organization (WHO) classification of tumors of the digestive system: review of selected updates on neuroendocrine neoplasms, appendiceal tumors, and molecular testing. Arch Pathol Lab Med 145(6):664–677

Article  PubMed  PubMed Central  Google Scholar 

Mollazadegan K, Welin S, Crona J (2021) Systemic treatment of gastroenteropancreatic neuroendocrine carcinoma. Curr Treat Opt Oncol 22(8)

Garcia-Carbonero R, Sorbye H, Baudin E et al (2016) ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology

Strosberg J, Nasir A, Coppola D et al (2009) Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol 40(9):1262–1268

Article  PubMed  Google Scholar 

Swisshelm K, Macek R, Kubbies M (2005) Role of claudins in tumorigenesis. Adv Drug Deliv Rev 57(6):919–928

Article  CAS  PubMed  Google Scholar 

Ding L, Lu Z, Lu Q et al (2013) The claudin family of proteins in human malignancy: a clinical perspective. Cancer Manag Res 5(1):367–375

PubMed  PubMed Central  Google Scholar 

Tsukita S, Tanaka H, Tamura A (2019) The Claudins: from tight junctions to biological systems. Trends Biochem Sci 44(2):141–152

Article  CAS  PubMed  Google Scholar 

Sahin U, Koslowski M, Dhaene K et al (2008) Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 14(23):7624–7634

Article  CAS  PubMed  Google Scholar 

Dottermusch M, Krüger S, Behrens HM et al (2019) Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study. Virchows Arch 475(5):563–571

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kyuno D, Takasawa A, Takasawa K et al (2022) Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers 10(1):1967080

Article  PubMed  Google Scholar 

Sahin U, Schuler M, Richly H et al (2018) A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur J Cancer 100:17–26

Article  CAS  PubMed  Google Scholar 

Türeci Ӧ, Mitnacht-Kraus R, Wöll S et al (2019) Characterization of zolbetuximab in pancreatic cancer models. OncoImmunology 8(1)

Sahin U, Türeci Ö, Manikhas G et al (2021) FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol 32(5):609–619

Article  CAS  PubMed  Google Scholar 

Ooki A, Yamaguchi K (2022) The dawn of precision medicine in diffuse-type gastric cancer. Ther Adv Med Oncol 14

Jia K, Chen Y, Sun Y et al (2022) Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. BMC Med 20(1)

Shah MA, Shitara K, Ajani JA et al (2023) Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 29(8):2133–2141

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klempner SJ, Lee KW, Shitara K et al (2023) ILUSTRO: Phase II multicohort trial of zolbetuximab in patients with advanced or metastatic Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res 29(19):3882–3891

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shitara K, Lordick F, Bang YJ et al (2023) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401(10389):1655–1668

Article  CAS  PubMed  Google Scholar 

Cao F, Huang XZ, Zhou LX et al (2019) Clinicopathologic features of high-grade G3 gastroenteropancreatic neuroendocrine tumors. Chin J Clin Oncol 46(22):1155–1159

Google Scholar 

Wong MT, Singhi AD, Larson BK et al (2023) Claudin-18 patterns of expression in the upper gastrointestinal tract and utility as a marker of gastric origin in neuroendocrine tumors. Arch Pathol Lab Med 147(5):559–567

Article  CAS  Google Scholar 

Niimi T, Nagashima K, Ward JM et al (2001) claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol 21(21):7380–7390

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rohde C, Yamaguchi R, Mukhina S et al (2019) Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Jpn J Clin Oncol 49(9):870–876

Article  PubMed  PubMed Central  Google Scholar 

Arpa G, Fassan M, Guerini C et al (2022) Claudin-18 expression in small bowel adenocarcinoma: a clinico-pathologic study. Virchows Arch 481(6):853–863

Article  CAS  PubMed  PubMed Central  Google Scholar 

Athauda A, Chau I (2021) Claudin 18.2—a FAST-moving target in gastric cancer? Ann Oncol 32(5):584–586

Article  CAS  PubMed  Google Scholar 

Wöll S, Schlitter AM, Dhaene K et al (2014) Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer 134(3):731–739

Article  PubMed  Google Scholar